# Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

> **NCT06682234** · PHASE2 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Filovirus Disease
- Postexposure Prophylaxis for Filovirus Disease

## Interventions

- **DRUG:** obeldesivir

## Key facts

- **NCT ID:** NCT06682234
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682234, "Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06682234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*